RuiYi, Genor Blaze Trail in China with JV for Rheumatoid Arthritis
By Dave Silver
Friday, May 17, 2013
TAIPEI, Taiwan In what is likely one of the first attempts by a foreign biopharma to complete the full range of clinical trials in China for a new biologic, leading to regulatory and market approval by Chinese drug approval authorities, therapeutic antibodies specialist RuiYi Inc., of La Jolla, Calif., and Shanghai, entered a collaboration agreement with Genor BioPharma Co. Ltd., of Shanghai, to develop its anti-IL-6 monoclonal antibody RYI-008 for rheumatoid arthritis (RA).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.